Based on the first contract with the Beijing CDC, Sinovac is expected to supply 375,000 doses of seasonal influenza vaccine, Anflu, valued at $1.3m.
Sinovac chairman, president and CEO Weidong Yin said that being selected as the first priority supplier of seasonal influenza vaccine by the Beijing CDC is further validation of the company’s quality assurance system.
"We look forward to working closely with the Beijing CDC to deliver our Anflu vaccine to the citizens under the vaccination campaign," Yin said.
Sinovac Biotech is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialisation of vaccines for hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza.